Trial Profile
A randomized, single blind, repeat dose, placebo-controlled, single-period, parallel group study to investigate the safety, tolerability and potential pharmacokinetic interactions between GW856553 and rosuvastatin (10mg), when co-administered in healthy adult male subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Losmapimod (Primary) ; Rosuvastatin
- Indications Acute coronary syndromes; Atherosclerosis; Cardiovascular disorders; Chronic obstructive pulmonary disease; Depressive disorders; Hypercholesterolaemia; Hyperlipidaemia; Hypertriglyceridaemia; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 20 May 2009 Exclusion criteria amended from NCT
- 21 Apr 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.